Anthropic and OpenEvidence Partner to Bring Free Medical AI to 100 Countries

Anthropic and OpenEvidence are partnering to extend free access to a medical AI tool for clinicians in about 100 low- and middle-income countries. The initiative aims to improve access to clinical knowledge in regions with limited resources, but it also faces questions about adaptation and sustainability.

Free Medical AI for Clinicians in Low-Income Countries

Anthropic and OpenEvidence are partnering to provide free access to a medical AI tool for clinicians in approximately 100 low- and middle-income countries, including Uganda, Angola, Sudan, Haiti, and Mongolia. According to The Next Web, the initiative aims to bridge gaps in access to up-to-date medical research and clinical guidelines for doctors in regions with limited resources.

How the Tool Works and Adapts to Local Needs

OpenEvidence, an AI tool already used by clinicians in the United States and Europe, answers clinical questions using peer-reviewed research and treatment guidelines. The tool is currently free for doctors in these regions, and its expansion to low- and middle-income countries is being framed as a step toward global health equity. According to The Next Web, US clinicians used the platform 42 million times in August alone, suggesting high engagement in markets where it is already available.

Anthropic provides the backend technology for OpenEvidence, while the latter focuses on adapting the system to regional healthcare needs. This includes modifying the tool to account for differences in disease patterns, diagnostic resources, and treatment protocols. For example, OpenEvidence has been working with health organizations in Rwanda and Botswana to refine the tool for local contexts.

In Rwanda, the project involved 45 local doctors and nurses who tested the AI tool and provided feedback on necessary adjustments. Similar efforts are likely underway in other target countries, though details remain limited.

Challenges and Criticisms

Despite the promise of this initiative, critics warn that medical AI systems trained primarily on data from high-income countries may not fully reflect how medicine is practiced in other regions. According to The Next Web, this misalignment could limit the tool’s effectiveness or even pose risks if not properly addressed.

Dr. Ahmed Bendary, a cardiologist cited by The Next Web, emphasized the importance of expanding such tools to places where access to major medical journals is limited. However, he and others caution that adaptation must go beyond superficial changes to ensure the AI aligns with local clinical realities.

The reliance on philanthropic support also raises questions about the long-term sustainability of the project. Market incentives alone would not justify the expansion, highlighting the need for alternative funding models to maintain and scale the initiative.

What this means

LazyFounders analysis — our interpretation, not reported fact.

This partnership signals a meaningful step toward addressing global health inequities by leveraging AI, but it also underscores the challenges of adapting technology designed for high-resource settings to low-resource environments.

For founders and operators in health tech, this initiative highlights two critical lessons:

1. Philanthropy as a Bridge: In markets where financial incentives are weak or absent, philanthropic collaborations can unlock access to technology that might otherwise remain out of reach. This model could inspire similar efforts in other underserved sectors, such as education or agriculture.

2. Localization is Non-Negotiable: The success of this tool hinges on its ability to adapt to regional disease patterns, diagnostic resources, and treatment protocols. Startups expanding into global markets must prioritize deep localization—not just translation—of their products. Superficial adjustments risk rendering the technology ineffective or, worse, harmful.

For the broader AI and healthcare industries, this project serves as a reminder that scalability isn’t just about reaching more users; it’s about ensuring the solution works meaningfully for all of them. The reliance on philanthropy also raises questions about sustainability. If AI is to become a truly global public good, business models may need to evolve beyond traditional monetization strategies.

Key takeaways

• Anthropic and OpenEvidence are offering free access to a medical AI tool for clinicians in approximately 100 low- and middle-income countries.
• The tool is already free for clinicians in the US and Europe and answers questions using peer-reviewed research and guidelines.
• Adaptation efforts in Rwanda and Botswana aim to align the tool with local healthcare needs, though concerns persist about its applicability.
• The project relies on philanthropic support, as market incentives alone would not justify the expansion.
• Even in low-resource settings, smartphone access among clinicians makes digital tools a viable option.

FAQ

What is OpenEvidence?

OpenEvidence is an AI-powered tool that answers clinical questions using peer-reviewed research and treatment guidelines. It is already used by doctors in the US and Europe and is now being expanded to low- and middle-income countries.

Why is this initiative focused on low- and middle-income countries?

The initiative aims to address disparities in access to up-to-date medical research and clinical guidelines. Many clinicians in these regions lack reliable access to major journals or evidence-based resources, making AI tools a potential solution to bridge the gap.

What are the main challenges facing this project?

Critics highlight concerns about the applicability of AI trained on data from high-income countries in low-resource settings. Adapting the tool to local disease patterns, diagnostic resources, and treatment protocols is essential but complex. Additionally, the project’s reliance on philanthropic support raises questions about long-term sustainability.

How is the AI tool being adapted for local needs?

OpenEvidence is working with health organizations in countries like Rwanda and Botswana to modify the tool. This includes testing with local clinicians, gathering feedback, and adjusting for differences in disease patterns and available resources.

Related on LazyFounders

• More health news